News Column

Department of Chemistry Reports Findings in Cancer Gene Therapy

June 16, 2014

By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Current study results on Biotechnology have been published. According to news reporting originating from Loja, Ecuador, by NewsRx correspondents, research stated, "Cancer remains a public health problem with a high unmet medical demand."

Our news editors obtained a quote from the research from the Department of Chemistry, "However, in recent decades, the knowledge of several functional molecular and biological traits that distinguish tumor cells from normal cells, known as the hallmarks of cancer as described by Hannahan and Weinberg, has led to new and modern therapeutic approaches against this disease. Most cancer drugs are deliberately developed for specific molecular targets that involve these hallmarks."

According to the news editors, the research concluded: "In this review, we address the currently available cancer drugs and development of new drugs from the perspective of their interaction with these hallmarks as well as the pathways and mechanisms involved."

For more information on this research see: Development of anticancer drugs based on the hallmarks of tumor cells. Tumor Biology, 2014;35(5):3981-3995. Tumor Biology can be contacted at: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands. (Springer -; Tumor Biology -

The news editors report that additional information may be obtained by contacting N. Bailon-Moscoso, UTPL, Dept. of Quim, Loja, Ecuador. Additional authors for this research include J.C. Romero-Benavides and P. Ostrosky-Wegman (see also Biotechnology).

Keywords for this news article include: Loja, Biotechnology, Ecuador, Oncology, South America, Cancer Gene Therapy

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Cancer Gene Therapy Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters